The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...

A substudy of the CHARM trial (see Trial Glossary below for expansion of all trial names mentioned in this article) has shown that the angiotensin receptor blocker (ARB) candesartan reduces the risk ...

Please provide your email address to receive an email when new articles are posted on . CAD was significantly prognostic of all-cause mortality in patients with heart failure. Mortality risk was ...

Mercy Health has launched an online heart disease risk assessment tool with the arrival of rising temperatures that can lead to heart issues. The tool, which is free and open to anyone, gives its ...

Current models of mortality risk after heart failure (HF) rely primarily on cardiac-specific clinical variables and may underestimate risk in elderly East Asian patients. Researchers from Japan used ...

Heart failure is a leading cause of hospitalization and long-term disability, with many individuals progressing from subclinical disease to overt symptoms ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most significant is ...

Less artery-clogging plaque in women's arteries did not appear to protect them from heart disease compared to men, according ...

Malnutrition can affect patients with various acute cardiovascular disease conditions, including acute coronary syndromes, arrhythmias, or valvular disease; however, most of the literature has focused ...

Management and decision making in univentricular heart disease and Fontan circulation, represents one of the most complex challenges in congenital ...

Health experts emphasize the importance of consulting a physician or undergoing a formal risk assessment before beginning any ...